New CEO commentary: “The Single-Cell Revolution”

On the company’s webpage, PHI’s CEO and founder Peter Egelberg comments the recently published innovation report from the UN agency World Intellectual Property Organization. The report sets PHI’s technology area, single-cell analysis, as the cutting-edge technology that is most likely to revolutionize healthcare over the next decade — outranking high-profile innovations such as regenerative medicine, immunotherapy and gene therapy, see phiab.com/commentary/the-single-cell-analysis-revolution.

For additional information, please contact:
Carolina Silvandersson
E-mail: ir@phiab.se
Web: www.phiab.com – Live cell imaging & analysis

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.